- Home
- WBTN vs GERN Comparison
WBTN vs GERN Comparison
Compare WBTN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBTN
- GERN
- Stock Information
- Founded
- WBTN 2005
- GERN 1990
- Country
- WBTN United States
- GERN United States
- Employees
- WBTN N/A
- GERN N/A
- Industry
- WBTN
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- WBTN
- GERN Health Care
- Exchange
- WBTN NYSE
- GERN Nasdaq
- Market Cap
- WBTN 1.7B
- GERN 2.8B
- IPO Year
- WBTN 2024
- GERN 1996
- Fundamental
- Price
- WBTN $12.17
- GERN $4.25
- Analyst Decision
- WBTN Buy
- GERN Strong Buy
- Analyst Count
- WBTN 5
- GERN 7
- Target Price
- WBTN $28.00
- GERN $6.93
- AVG Volume (30 Days)
- WBTN 568.4K
- GERN 7.5M
- Earning Date
- WBTN 08-08-2024
- GERN 10-31-2024
- Dividend Yield
- WBTN N/A
- GERN N/A
- EPS Growth
- WBTN N/A
- GERN N/A
- EPS
- WBTN N/A
- GERN N/A
- Revenue
- WBTN $1,299,544,000.00
- GERN $1,373,000.00
- Revenue This Year
- WBTN N/A
- GERN $22,291.14
- Revenue Next Year
- WBTN N/A
- GERN $385.35
- P/E Ratio
- WBTN N/A
- GERN N/A
- Revenue Growth
- WBTN 18.84
- GERN 205.11
- 52 Week Low
- WBTN $11.15
- GERN $1.64
- 52 Week High
- WBTN $25.66
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- WBTN N/A
- GERN 40.22
- Support Level
- WBTN N/A
- GERN $4.21
- Resistance Level
- WBTN N/A
- GERN $4.79
- Average True Range (ATR)
- WBTN 0.00
- GERN 0.19
- MACD
- WBTN 0.00
- GERN -0.04
- Stochastic Oscillator
- WBTN 0.00
- GERN 6.90
About WBTN WEBTOON ENTERTAINMENT INC
Webtoon Entertainment Inc is a global storytelling platform where a vibrant community of creators and users discover, create and share new content. It has pioneered a cultural movement by revolutionizing the storytelling format and democratizing content creation and publication connecting 24 million creators with approximately 170 million monthly active users in over 150 countries around the world.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.